Sort By

  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • James Dunn

Thinking ahead – ASX MedTech leaders

Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…
James Dunn | 12th Oct 2020 | More
Earnings Season is Here – and It’s Going to be Ugly

With July coming to a close, it’s time for reporting season – and this year, it’s not going to be pretty.
James Dunn | 28th Jul 2020 | More